NCT06319963View on ClinicalTrials.gov

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
HPV-Related Cervical CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Two IM injections Lenti-HPV-07

two Lenti-HPV-07 intramuscular injections one month apart

DRUG

One IM injection Lenti-HPV-07

a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.

Trial Locations (4)

32827

RECRUITING

Florida Cancer Specialists (from Sarah Canon research Institute), Orlando

33606

RECRUITING

Tampa General Hospital, Tampa

33612

RECRUITING

Moffitt Cancer Center, Tampa

74146

RECRUITING

Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa

All Listed Sponsors
lead

Theravectys S.A.

INDUSTRY